226 related articles for article (PubMed ID: 25665046)
1. A multigene array for measurable residual disease detection in AML patients undergoing SCT.
Goswami M; McGowan KS; Lu K; Jain N; Candia J; Hensel NF; Tang J; Calvo KR; Battiwalla M; Barrett AJ; Hourigan CS
Bone Marrow Transplant; 2015 May; 50(5):642-51. PubMed ID: 25665046
[TBL] [Abstract][Full Text] [Related]
2. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
[TBL] [Abstract][Full Text] [Related]
4. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
[TBL] [Abstract][Full Text] [Related]
6. Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes.
Yu S; Fan Z; Ma L; Wang Y; Huang F; Zhang Q; Huang J; Wang S; Xu N; Xuan L; Xiong M; Han L; Sun Z; Zhang H; Liu H; Yu G; Shi P; Xu J; Wu M; Guo Z; Xiong Y; Duan C; Sun J; Liu Q; Zhang Y
JAMA Netw Open; 2021 Jul; 4(7):e2115991. PubMed ID: 34232303
[TBL] [Abstract][Full Text] [Related]
7. Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML.
Lambert J; Lambert J; Thomas X; Marceau-Renaut A; Micol JB; Renneville A; Clappier E; Hayette S; Récher C; Raffoux E; Pigneux A; Berthon C; Terré C; Celli-Lebras K; Castaigne S; Boissel N; Rousselot P; Preudhomme C; Dombret H; Duployez N
Blood Adv; 2021 Dec; 5(23):5258-5268. PubMed ID: 34625784
[TBL] [Abstract][Full Text] [Related]
8. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia.
Shah MV; Jorgensen JL; Saliba RM; Wang SA; Alousi AM; Andersson BS; Bashir Q; Ciurea SO; Kebriaei P; Marin D; Patel KP; Popat UR; Rezvani K; Rondon G; Shpall EJ; Champlin RE; Oran B
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1514-1520. PubMed ID: 29448058
[TBL] [Abstract][Full Text] [Related]
9. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
[TBL] [Abstract][Full Text] [Related]
10. Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission.
Jia X; Liao N; Yu S; Li H; Liu H; Zhang H; Xu J; Yao Y; He H; Yu G; Liu Q; Zhang Y; Shi P
Cancer Med; 2024 Feb; 13(4):e7074. PubMed ID: 38457215
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission.
Chen J; Yang L; Fan Y; Xu Y; Han Y; Tang X; Qiu H; Fu C; Miao M; Chen F; Wu D
Biol Blood Marrow Transplant; 2018 Apr; 24(4):779-788. PubMed ID: 29289758
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.
Rossi G; Carella AM; Minervini MM; Savino L; Fontana A; Pellegrini F; Greco MM; Merla E; Quarta G; Loseto G; Capalbo S; Palumbo G; Cascavilla N
Leuk Lymphoma; 2013 Dec; 54(12):2660-6. PubMed ID: 23547840
[TBL] [Abstract][Full Text] [Related]
13. Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: a comparison between multiparameter flow cytometry and Wilms' tumor 1 expression.
Rossi G; Carella AM; Minervini MM; di Nardo F; Waure Cd; Greco MM; Merla E; Cillis GP; Di Renzo N; Melpignano A; Capalbo S; Palumbo G; Pisapia G; Cascavilla N
Leuk Res; 2015 Feb; 39(2):138-43. PubMed ID: 25498507
[TBL] [Abstract][Full Text] [Related]
14. Wilms' tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.
Deng DX; Wen JJ; Cheng YF; Zhang XH; Xu LP; Wang Y; Yan CH; Chen YH; Chen H; Han W; Wang FR; Wang JZ; Qin YZ; Liu KY; Huang XJ; Zhao XS; Mo XD
BMC Cancer; 2021 Mar; 21(1):292. PubMed ID: 33740924
[TBL] [Abstract][Full Text] [Related]
15. Post-Transplantation Multicolored Flow Cytometry-Minimal Residual Disease Status on Day 100 Predicts Outcomes for Patients With Refractory Acute Myeloid Leukemia.
Klyuchnikov E; Badbaran A; Massoud R; Fritsche-Friedland U; Janson D; Ayuk F; Christopeit M; Wolschke C; Bacher U; Kröger N
Transplant Cell Ther; 2022 May; 28(5):267.e1-267.e7. PubMed ID: 35066212
[TBL] [Abstract][Full Text] [Related]
16. Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Liu J; Zhao XS; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Fan QZ; Huang XJ; Chang YJ
Chin Med J (Engl); 2018 Dec; 131(23):2808-2816. PubMed ID: 30511683
[TBL] [Abstract][Full Text] [Related]
17. Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes.
Yu S; Lin T; Nie D; Zhang Y; Sun Z; Zhang Q; Wang C; Xiong M; Fan Z; Huang F; Xu N; Liu H; Yu G; Zhang H; Shi P; Xu J; Xuan L; Guo Z; Wu M; Han L; Xiong Y; Sun J; Wang Y; Liu Q
Blood Cancer J; 2021 Dec; 11(12):195. PubMed ID: 34873148
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of minimal residual disease in childhood acute myeloid leukemia.
Miyamura T; Sakata N; Okamura T; Yasui M; Inoue M; Yagi K; Sako M; Komada Y; Matsuyama T; Oda M; Park YD; Kawa K
Int J Hematol; 2004 Apr; 79(3):243-9. PubMed ID: 15168592
[TBL] [Abstract][Full Text] [Related]
19. WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation.
Zhong L; Wei L; Chen J; Huang X; Gong Y; Lu Y
Mol Diagn Ther; 2015 Aug; 19(4):205-12. PubMed ID: 26138637
[TBL] [Abstract][Full Text] [Related]
20. WT1 Gene Expression in Peripheral Blood Before and After Allogeneic Stem Cell Transplantation is a Clinically Relevant Prognostic Marker in AML - A Single-center 14-year Experience.
Valkova V; Vydra J; Markova M; Cerovska E; Vrana M; Marinov I; Cechova H; Cetkovsky P; Vitek A; Salek C
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e145-e151. PubMed ID: 33160932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
